Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21075587 | 1.00 | ATM (0.39) | ATMSMN1; SMN2HSD11B1 | |
| SCHEMBL19083915 | 0.85 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL24021148 | 0.83 | HSD17B10 (0.37) | SMN1; SMN2HSD11B1 | |
| SCHEMBL20446616 | 0.83 | HSD17B10 (0.37) | SMN1; SMN2HSD11B1 | |
| SCHEMBL21075266 | 0.76 | ATM (0.46) | ATMSMN1; SMN2 | |
| SCHEMBL17428818 | 0.76 | ATM (0.46) | ATMSMN1; SMN2 | |
| SCHEMBL19083941 | 0.72 | ATM (0.43) | ATM | |
| SCHEMBL21996628 | 0.71 | PTPN1 (0.37) | SMN1; SMN2HSD11B1 | |
| SCHEMBL23995713 | 0.70 | TSHR (0.32) | SMN1; SMN2 | |
| SCHEMBL23345231 | 0.70 | TSHR (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885SMN1; SMN2 2803/4885HSD11B1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.